<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="systematic-review"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Cardiovasc Med</journal-id><journal-id journal-id-type="iso-abbrev">Front Cardiovasc Med</journal-id><journal-id journal-id-type="publisher-id">Front. Cardiovasc. Med.</journal-id><journal-title-group><journal-title>Frontiers in Cardiovascular Medicine</journal-title></journal-title-group><issn pub-type="epub">2297-055X</issn><publisher><publisher-name>Frontiers Media S.A.</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC12098576</article-id><article-id pub-id-type="doi">10.3389/fcvm.2025.1496334</article-id><article-categories><subj-group subj-group-type="heading"><subject>Cardiovascular Medicine</subject><subj-group><subject>Systematic Review</subject></subj-group></subj-group></article-categories><title-group><article-title>Antithrombotic strategies after transcatheter aortic valve replacement a network meta-analysis</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Shi</surname><given-names>Mengxiao</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/2701506/overview"/><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/software/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name><surname>Wu</surname><given-names>Ying</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/project-administration/"/><role content-type="https://credit.niso.org/contributor-roles/resources/"/><role content-type="https://credit.niso.org/contributor-roles/supervision/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Zhou</surname><given-names>Qing</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="cor1" ref-type="corresp">*</xref><uri xlink:href="https://loop.frontiersin.org/people/1718217/overview"/><role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/resources/"/><role content-type="https://credit.niso.org/contributor-roles/supervision/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/></contrib></contrib-group><aff id="aff1"><label><sup>1</sup></label><institution>Department of Cardio-Thoracic Surgery, Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine</institution>, <addr-line>Nanjing, Jiangsu</addr-line>, <country>China</country></aff><aff id="aff2"><label><sup>2</sup></label><institution>Department of Cardio-thoracic Surgery, Nanjing Drum Tower Hospital</institution>, <addr-line>Nanjing</addr-line>, <country>China</country></aff><author-notes><fn fn-type="edited-by"><p><bold>Edited by:</bold> Carlos Jerjes-Sanchez, Tecnol&#x000f3;gico de Monterrey, Mexico</p></fn><fn fn-type="edited-by"><p><bold>Reviewed by:</bold> Bibhu Mohanty, University of South Florida, United States</p><p>Victor Alfonso Jimenez Diaz, Alvaro Cunqueiro Hospital, Spain</p></fn><corresp id="cor1"><label>*</label><bold>Correspondence:</bold> Qing Zhou <email>zhouqing_penn@163.com</email></corresp></author-notes><pub-date pub-type="epub"><day>09</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>12</volume><elocation-id>1496334</elocation-id><history>
<date date-type="received"><day>14</day><month>9</month><year>2024</year></date>
<date date-type="accepted"><day>24</day><month>4</month><year>2025</year></date>
</history><permissions><copyright-statement>&#x000a9; 2025 Shi, Wu and Zhou.</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Shi, Wu and Zhou</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License (CC BY)</ext-link>. The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><abstract><p>The optimal antithrombotic regimen for patients without an indication for oral anticoagulation (OAC) after transcatheter aortic valve replacement (TAVR) remains unclear. We conducted a network meta-analysis of randomized controlled trials to clarify the best postoperative antithrombotic regimen. We searched literature databases including PubMed/Medline and Cochrane up to June 2024. Safety endpoints included all-cause death, cardiovascular death, major/life-threatening bleeding, and minor bleeding during follow-up. Efficacy endpoints encompassed ischaemic stroke transient ischemic attack (TIA), systemic embolism, hypoattenuated leaflet thickening (HALT), and reduced leaflet motion (RELM). Outcomes were assessed during the follow-up period specified in each trial (range:3&#x02013;24 months). The results were statistically analyzed using R 4.3.2 and Stata 16 software. The final analysis included seven randomized controlled trials. Single antiplatelet therapy (SAPT) showed a lower incidence of major/life-threatening bleeding compared to the direct oral anticoagulants (DOACs) group (OR: 0.68, 95% CI: 0.47&#x02013;0.99, <italic>P</italic>&#x02009;=&#x02009;0.002) during the 3&#x02013;24 month post-TAVR period. However, no significant differences were found in other safety or efficacy endpoints. SAPT is the preferred treatment strategy for TAVR patients without anticoagulation indications.</p><sec><title>Systematic Review Registration</title><p>identifier, PROSPERO registration number: CRD42024584735.</p></sec></abstract><kwd-group><kwd>TAVR</kwd><kwd>antithrombotic therapy</kwd><kwd>antiplatelet therapy</kwd><kwd>anticoagulation therapy</kwd><kwd>meta-analysis</kwd></kwd-group><funding-group><award-group><funding-source id="cn001">Jiangsu Provincial Health and Health Commission</funding-source><award-id award-type="contract" rid="cn001">ZD2021023</award-id></award-group><funding-statement>The author(s) declare that financial support was received for the research and/or publication of this article. This research is supported by the key project of medical research of Jiangsu Provincial Health and Health Commission. Grant number ZD2021023.</funding-statement></funding-group><counts><fig-count count="4"/><table-count count="2"/><equation-count count="0"/><ref-count count="27"/><page-count count="10"/><word-count count="0"/></counts><custom-meta-group><custom-meta><meta-name>section-at-acceptance</meta-name><meta-value>Thrombosis and Haemostasis</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="s1"><title>Introduction</title><p>TAVR has become the leading transcatheter approach for replacing a narrowed aortic valve in patients with severe symptomatic aortic stenosis (<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B2" ref-type="bibr">2</xref>). The success rate of the TAVR procedure has improved over time; however, it remains associated with long-term cardiovascular complications requiring targeted antithrombotic management, such as myocardial infarction, stroke, major bleeding, valve thrombosis, and systemic embolism (<xref rid="B3" ref-type="bibr">3</xref>, <xref rid="B4" ref-type="bibr">4</xref>).</p><p>Optimal medical management of patients after TAVR is crucial, focusing on antithrombotic therapy to prevent valve thrombosis and other complications while balancing bleeding risks. Guidelines from the American College of Cardiology (ACC) and the American Heart Association (AHA) in 2020 recommended SAPT after TAVR for patients without an indication for OAC (<xref rid="B5" ref-type="bibr">5</xref>). Recent randomized controlled trials have shown that SAPT after TAVR in patients without an indication for OAC did not increase the risk of ischemic events and reduced bleeding risk compared to dual antiplatelet therapy (DAPT) (<xref rid="B1" ref-type="bibr">1</xref>).</p><p>Recent studies indicate that DOAC reduce the incidence of HALT and RELM, which are imaging biomarkers associated with subclinical valve thrombosis. However, current randomized controlled trials (RCTs) have not demonstrated conclusive evidence that DOACs improve long-term valve durability or hemodynamic performance. For instance, the GALILEO trial showed a reduction in HALT and RELM with rivaroxaban compared to antiplatelet therapy, but no significant difference in clinical valve dysfunction endpoints was observed (<xref rid="B6" ref-type="bibr">6</xref>). A limitation of existing studies is the heterogeneity of control groups, where combinations of DAPT, SAPT, and VKA may introduce confounding factors. This heterogeneity complicates the direct comparison of antithrombotic strategies and their impact on valve outcomes (<xref rid="B7" ref-type="bibr">7</xref>).</p><p>A meta-analysis suggested that SAPT is preferable after TAVR, although it was compared with the DAPT group, and did not address important thrombotic events like HALT and RELM (<xref rid="B8" ref-type="bibr">8</xref>). Few randomized trials have tested DOACs for preventing thromboembolic events after TAVR in recent years (<xref rid="B9" ref-type="bibr">9</xref>).</p><p>Therefore, it remains unclear whether SAPT, DAPT, DOACs, or SAPT combined with VKA are superior, particularly regarding the balance between bleeding and thrombotic events. To clarify this equipoise, we conducted a meta-analysis comparing the risks and benefits of various antithrombotic regimens after TAVR, particularly compared to DOACs. This analysis focused on recent randomized controlled trials involving patients without indications for anticoagulation.</p></sec><sec sec-type="methods" id="s2"><title>Methods</title><sec id="s2a"><title>Study design</title><p>This systematic review and meta-analysis was performed in adherence to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines (<xref rid="B10" ref-type="bibr">10</xref>) and the Cochrane Handbook for Systematic Reviews of Interventions (<xref rid="B11" ref-type="bibr">11</xref>). Given the nature of this study as a secondary analysis of published data, formal ethical approval and patient consent were waived.</p></sec><sec id="s2b"><title>Database search</title><p>This systematic review was registered with PROSPERO in August 2024 (PROSPERO registration number: CRD42024584735). We searched PubMed/Medline and the Cochrane Library for randomized controlled trials comparing antithrombotic strategies after TAVR up to 1 June 2024. Detailed search strategies are provided in <xref rid="s11" ref-type="sec">Supplementary Table S1</xref>.</p></sec><sec id="s2c"><title>Risk of bias assessment</title><p>The Cochrane Risk of Bias-2 (ROB-2) tool (<xref rid="B10" ref-type="bibr">10</xref>) was used to evaluate bias across all included trials. Studies were appraised based on six predefined domains: (1) random sequence generation, (2) allocation concealment, (3) participant blinding, (4) personnel blinding, (5) selective reporting, and (6) incomplete outcome data. Each domain was classified as having low, high, or unclear risk of bias, with an overall risk-of-bias summary provided for each study. Two independent reviewers performed the bias assessment, with discrepancies resolved through consensus discussion.</p></sec><sec id="s2d"><title>Inclusion and exclusion criteria</title><p>Inclusion criteria: (1) post-TAVR patients without indications for anticoagulation. (2) type of study was a randomized controlled study. (3) groups receiving various antithrombotic therapies. (4) Reported outcomes encompassed safety endpoints: all-cause death, cardiovascular death, major/life-threatening hemorrhage, minor hemorrhage, and efficacy over follow-up. Additional endpoints were ischemic stroke/TIA, systemic embolism, HALT, and RELM events.</p><p>Exclusion criteria: (1) patients needing OAC anticoagulation. (2) non-randomized controlled studies (e.g., retrospective analyses). (3) any conditions deemed unsuitable by investigators.</p><p>DOAC served as the control group, with other antithrombotic strategies compared against it.</p></sec><sec id="s2e"><title>Research screening</title><p>All identified citations were imported into EndNote for deduplication. Two researchers independently reviewed the titles and abstracts to ensure compliance. Discrepancies in the study selection process were resolved through consultation and consensus with the other authors.</p></sec><sec id="s2f"><title>Data extraction</title><p>Data extraction was obtained in the included RCTs. This included extracting trial characteristics (authors, publication year, study design, subject numbers, experimental and control groups, follow-up duration), study baseline characteristics [age, sex, BMI, comorbidities, Society for Thoracic Surgery (STS) score, European Cardiovascular Surgery Risk Factor Score EURO SCORE], and the predefined endpoints. The authors employed a standardized extraction form, resolving discrepancies through consensus.</p></sec><sec id="s2g"><title>Statistical analysis</title><p>Statistical analyses were performed using R version 4.3.2 and Stata 16. Dichotomous outcomes were pooled using the odds ratio (OR) and 95% confidence interval (CI) as effect measures. A random-effects model was applied for meta-analyses. Statistical significance was defined as <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05.</p></sec></sec><sec id="s3"><title>Result</title><sec id="s3a"><title>Search results incorporated</title><p>A total of 210 studies were retrieved from PubMed/Medline (37) and Cochrane (173). Twenty duplicate studies were removed; One hundred and eighty-two irrelevant articles were excluded based on non-RCT designs, non-TAVR populations, or lack of antithrombotic strategy comparisons; there were no unretrieved reports. Among the 8 studies, one study with an incorrect population was excluded, and finally 7 studies were included. The detailed PRISMA flowchart process is depicted in <xref rid="F1" ref-type="fig">Figure&#x000a0;1</xref>.</p><fig position="float" id="F1"><label>Figure 1</label><caption><p>PRISMA flow chart in the screening process.</p></caption><graphic xlink:href="fcvm-12-1496334-g001" position="float"/></fig><fig position="float" id="F2"><label>Figure 2</label><caption><p>Bias risk assessment in the study: <bold>(A)</bold> risk of bias graph; <bold>(B)</bold> risk of bias summary; low&#x02009;=&#x02009;green; unclear&#x02009;=&#x02009;yellow; height&#x02009;=&#x02009;red.</p></caption><graphic xlink:href="fcvm-12-1496334-g002" position="float"/></fig></sec><sec id="s3b"><title>Characteristics of inclusion in the study</title><p>Seven randomized controlled trials involving 3,164 patients were included (<xref rid="B6" ref-type="bibr">6</xref>, <xref rid="B12" ref-type="bibr">12</xref>&#x02013;<xref rid="B17" ref-type="bibr">17</xref>). 602 cases in the DAPT group, 1,052 in the DOAC group, 1,463 in the SAPT group, and 44 in the VKA&#x02009;+&#x02009;SAPT group. The characteristics of the included research are shown in <xref rid="T1" ref-type="table">Table&#x000a0;1</xref>. The baselines included in the study are shown in <xref rid="T2" ref-type="table">Table&#x000a0;2</xref>.</p><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Incorporate research characteristics.</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="center" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">Study ID</th><th valign="top" align="center" rowspan="1" colspan="1">Total patients</th><th valign="top" align="center" rowspan="1" colspan="1">Experimental group</th><th valign="top" align="center" rowspan="1" colspan="1">Drug dose</th><th valign="top" align="center" rowspan="1" colspan="1">Control group</th><th valign="top" align="center" rowspan="1" colspan="1">Drug dose</th><th valign="top" align="center" rowspan="1" colspan="1">Follow up (Months)</th><th valign="top" align="center" rowspan="1" colspan="1">Primary outcome</th><th valign="top" align="center" rowspan="1" colspan="1">TAVI access</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Duk-Woo Park et al. 2022 (<xref rid="B12" ref-type="bibr">12</xref>) (ADAPT-TAVR&#x0ff09;</td><td valign="top" align="center" rowspan="1" colspan="1">229</td><td valign="top" align="left" rowspan="1" colspan="1">DAPT</td><td valign="top" align="left" rowspan="1" colspan="1">Aspirin (100&#x02005;mg) plus clopidogrel (75&#x02005;mg) Once daily</td><td valign="top" align="left" rowspan="1" colspan="1">Edoxaban</td><td valign="top" align="left" rowspan="1" colspan="1">Edoxaban 60 or 30&#x02005;mg Once daily</td><td valign="top" align="center" rowspan="1" colspan="1">6</td><td valign="top" align="left" rowspan="1" colspan="1">Valve leaflet thrombosis</td><td valign="top" align="left" rowspan="1" colspan="1">Transfemoral</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">George D. Dangas et al. 2019 (<xref rid="B6" ref-type="bibr">6</xref>) (GALILEO)</td><td valign="top" align="center" rowspan="1" colspan="1">1644</td><td valign="top" align="left" rowspan="1" colspan="1">SAPT</td><td valign="top" align="left" rowspan="1" colspan="1">Aspirin at a dose of 75&#x02013;100&#x02005;mg daily and clopidogrel at a dose of 75&#x02005;mg. once daily for 3 months. Followed by aspirin monotherapy (75&#x02013;100&#x02005;mg daily)</td><td valign="top" align="left" rowspan="1" colspan="1">Rivaroxaban</td><td valign="top" align="left" rowspan="1" colspan="1">Rivaroxaban at a dose of 10&#x02005;mg daily plus aspirin at a dose of 75&#x02013;100&#x02005;mg daily for 3 months, followed by rivaroxaban monotherapy (10&#x02005;mg daily)</td><td valign="top" align="center" rowspan="1" colspan="1">24</td><td valign="top" align="left" rowspan="1" colspan="1">The composite of all-cause mortality, MI, stroke/TIA, SE, valve thrombosis, and DVT/PE</td><td valign="top" align="left" rowspan="1" colspan="1">N/A</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Gian Paolo Ussia et al. 2011 (<xref rid="B13" ref-type="bibr">13</xref>) USSIA&#x0ff09;</td><td valign="top" align="center" rowspan="1" colspan="1">79</td><td valign="top" align="left" rowspan="1" colspan="1">SAPT</td><td valign="top" align="left" rowspan="1" colspan="1">Aspirin 100&#x02005;mg Once daily</td><td valign="top" align="left" rowspan="1" colspan="1">DAPT</td><td valign="top" align="left" rowspan="1" colspan="1">75&#x02005;mg clopidogrel plus aspirin 100&#x02005;mg</td><td valign="top" align="center" rowspan="1" colspan="1">6</td><td valign="top" align="left" rowspan="1" colspan="1">The primary the endpoint was the composite of major adverse cardiac and cerebrovascular events (MACCE)</td><td valign="top" align="left" rowspan="1" colspan="1">There were 77 patients in the transfemoral group. Among them, there were 38 patients in the DAPT group and 39 patients in the SAPT group. There were 2 patients in the trans- subclavian group, and both of them were in the DAPT group.</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Josep Rod&#x000e9;s-Cabau MD et al. 2017 (<xref rid="B14" ref-type="bibr">14</xref>) (ARTE)</td><td valign="top" align="center" rowspan="1" colspan="1">222</td><td valign="top" align="left" rowspan="1" colspan="1">SAPT</td><td valign="top" align="left" rowspan="1" colspan="1">Aspirin or acetylsalicylic acid (80&#x02013;100&#x02005;mg/day)</td><td valign="top" align="left" rowspan="1" colspan="1">DAPT</td><td valign="top" align="left" rowspan="1" colspan="1">Aspirin or acetylsalicylic acid (80&#x02013;100&#x02005;mg/day) plus clopidogrel (75&#x02005;mg/day)</td><td valign="top" align="center" rowspan="1" colspan="1">12</td><td valign="top" align="left" rowspan="1" colspan="1">The primary endpoint was the rate of death, MI, ischemic stroke or TIA, or major or life threatening bleeding at 3-month follow-up.</td><td valign="top" align="left" rowspan="1" colspan="1">Transfemoral: 72.1% in the DAPT group and 65.8% in the SAPT group. Via Transapical approach: 16.2% in the DAPT group and 18.0% in the SAPT group. Via Transaortic approach: 9.0% in the DAPT group and 12.6% in the SAPT group. Via Transcarotid approach: 2.7% in the DAPT group and 3.6% in the SAPT group.</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Rogers Toby et al. 2021 (<xref rid="B15" ref-type="bibr">15</xref>)</td><td valign="top" align="center" rowspan="1" colspan="1">94</td><td valign="top" align="left" rowspan="1" colspan="1">SAPT</td><td valign="top" align="left" rowspan="1" colspan="1">Aspirin 75&#x02013;100&#x02005;mg daily and 3&#x02013;6 months of clopidogrel (75&#x02005;mg daily)</td><td valign="top" align="left" rowspan="1" colspan="1">VKA&#x02009;+&#x02009;SAPT</td><td valign="top" align="left" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">15</td><td valign="top" align="left" rowspan="1" colspan="1">The primary effectiveness end point of the study was a composite of the following at 30 days: HALT, at least moderate RELM, hemodynamic dysfunction, stroke, or transient ischemic attack.</td><td valign="top" align="left" rowspan="1" colspan="1">Transfemoral</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Ole De Backer et al. 2020 (<xref rid="B16" ref-type="bibr">16</xref>) (GALILEO-4D)</td><td valign="top" align="center" rowspan="1" colspan="1">231</td><td valign="top" align="left" rowspan="1" colspan="1">SAPT</td><td valign="top" align="left" rowspan="1" colspan="1">Aspirin at a dose of 75&#x02013;100&#x02005;mg daily and clopidogrel at a dose of 75&#x02005;mg. once daily for 3 months. Followed by aspirin monotherapy (75&#x02013;100&#x02005;mg aily)</td><td valign="top" align="left" rowspan="1" colspan="1">Rivaroxaban</td><td valign="top" align="left" rowspan="1" colspan="1">Rivaroxaban at a dose of 10&#x02005;mg aily plus aspirin at a dose of 75&#x02013;100&#x02005;mg daily or 3 months, followed by rivaroxaban monotherapy (10&#x02005;mg daily)</td><td valign="top" align="center" rowspan="1" colspan="1">3</td><td valign="top" align="left" rowspan="1" colspan="1">At least 1 prosthetic valve leaflet with RELM of grade 3 or 4 or HALT of grade 3 or 4</td><td valign="top" align="left" rowspan="1" colspan="1">N/A</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Jorn Brouwer et al. 2020 (<xref rid="B17" ref-type="bibr">17</xref>) (Popular TAVI)</td><td valign="top" align="center" rowspan="1" colspan="1">665</td><td valign="top" align="left" rowspan="1" colspan="1">SAPT</td><td valign="top" align="left" rowspan="1" colspan="1">Aspirin at a dose of 80&#x02013;100&#x02005;mg daily</td><td valign="top" align="left" rowspan="1" colspan="1">DAPT</td><td valign="top" align="left" rowspan="1" colspan="1">Aspirin&#x02013;clopidogrel group were assigned to receive aspirin at a dose of 80&#x02013;100&#x02005;mg daily plus clopidogrel at a dose of 75&#x02005;mg daily for 3 months, followed by aspirin alone (80&#x02013;100&#x02005;mg daily) for the entire duration of the trial</td><td valign="top" align="center" rowspan="1" colspan="1">12</td><td valign="top" align="left" rowspan="1" colspan="1">The two primary outcomes were all bleeding (including minor, major, and life-threatening or disabling bleeding) and non&#x02013;procedure-related bleeding over a period of 12 months. The first secondary outcome was a composite of bleeding or thromboembolic events The other secondary outcome was a composite of death from cardiovascular causes, ischemic stroke, or myocardial infarction</td><td valign="top" align="left" rowspan="1" colspan="1">N/A</td></tr></tbody></table><table-wrap-foot><fn id="table-fn1"><p>TIA, transient ischemic attack; HALT, hypoattenuated leaflet thickening; RELM, reduced leaflet motion; SAPT, single antiplatelet therapy; DAPT, dual antiplatelet therapy (DAPT); OAC, oral anticoagulant; DOACs, direct oral anticoagulants; VKA, vitamin K antagonist; DVT/PE, <sans-serif>d</sans-serif>eep vein thrombosis and pulmonary embolism.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="T2"><label>Table 2</label><caption><p>Baseline for inclusion in the study.</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><th valign="top" align="left" rowspan="2" colspan="1">Characteristics</th><th valign="top" align="center" colspan="2" rowspan="1">Duk Woo Park et al. (ADAPT-TAVR)</th><th valign="top" align="center" colspan="2" rowspan="1">GeorgeD Dangas et al. (GALILEO)</th><th valign="top" align="center" colspan="2" rowspan="1">Gian Paolo Ussia et al.</th><th valign="top" align="center" colspan="2" rowspan="1">Josep Rod&#x000e9;s Cabau et al. (ARTE)</th><th valign="top" align="center" colspan="2" rowspan="1">Rogers T et al.</th><th valign="top" align="center" colspan="2" rowspan="1">Becker et al. (GALILEO-4D)</th><th valign="top" align="center" colspan="2" rowspan="1">Jorn Brouwer et al.</th></tr><tr><th valign="top" align="center" rowspan="1" colspan="1">NOAC</th><th valign="top" align="center" rowspan="1" colspan="1">DAPT</th><th valign="top" align="center" rowspan="1" colspan="1">DOAC</th><th valign="top" align="center" rowspan="1" colspan="1">SAPT</th><th valign="top" align="center" rowspan="1" colspan="1">DAPT</th><th valign="top" align="center" rowspan="1" colspan="1">SAPT</th><th valign="top" align="center" rowspan="1" colspan="1">DAPT</th><th valign="top" align="center" rowspan="1" colspan="1">SAPT</th><th valign="top" align="center" rowspan="1" colspan="1">SAPT</th><th valign="top" align="center" rowspan="1" colspan="1">OAC&#x02009;+&#x02009;SAPT</th><th valign="top" align="center" rowspan="1" colspan="1">DOAC</th><th valign="top" align="center" rowspan="1" colspan="1">SAPT</th><th valign="top" align="center" rowspan="1" colspan="1">SAPT</th><th valign="top" align="center" rowspan="1" colspan="1">DAPT</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Age, (year)</td><td valign="top" align="center" rowspan="1" colspan="1">80.2 (5.2)</td><td valign="top" align="center" rowspan="1" colspan="1">80 (5.3)</td><td valign="top" align="center" rowspan="1" colspan="1">80.4 (7)</td><td valign="top" align="center" rowspan="1" colspan="1">80.8 (6)</td><td valign="top" align="center" rowspan="1" colspan="1">81 (4)</td><td valign="top" align="center" rowspan="1" colspan="1">80 (6)</td><td valign="top" align="center" rowspan="1" colspan="1">79 (9)</td><td valign="top" align="center" rowspan="1" colspan="1">79 (9)</td><td valign="top" align="center" rowspan="1" colspan="1">73.1 (5.7)</td><td valign="top" align="center" rowspan="1" colspan="1">73.6 (4.0)</td><td valign="top" align="center" rowspan="1" colspan="1">79.7 (7.3)</td><td valign="top" align="center" rowspan="1" colspan="1">80.5 (6.2)</td><td valign="top" align="center" rowspan="1" colspan="1">80.4 (6.2)</td><td valign="top" align="center" rowspan="1" colspan="1">79.5 (6.4)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Male, <italic>n</italic> (%)</td><td valign="top" align="center" rowspan="1" colspan="1">49 (44.1)</td><td valign="top" align="center" rowspan="1" colspan="1">47 (39.8)</td><td valign="top" align="center" rowspan="1" colspan="1">426 (51.6)</td><td valign="top" align="center" rowspan="1" colspan="1">405 (49.5)</td><td valign="top" align="center" rowspan="1" colspan="1">16 (41)</td><td valign="top" align="center" rowspan="1" colspan="1">20 (50)</td><td valign="top" align="center" rowspan="1" colspan="1">70 (63.1)</td><td valign="top" align="center" rowspan="1" colspan="1">59 (53.2)</td><td valign="top" align="center" rowspan="1" colspan="1">37 (74.0)</td><td valign="top" align="center" rowspan="1" colspan="1">29 (65.9)</td><td valign="top" align="center" rowspan="1" colspan="1">74 (64.3)</td><td valign="top" align="center" rowspan="1" colspan="1">74 (63.8)</td><td valign="top" align="center" rowspan="1" colspan="1">167 (50.5)</td><td valign="top" align="center" rowspan="1" colspan="1">174 (52.1)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">BMI, (kg/m2)</td><td valign="top" align="center" rowspan="1" colspan="1">24.(3.8&#x0ff09;</td><td valign="top" align="center" rowspan="1" colspan="1">24.8 (4.3)</td><td valign="top" align="center" rowspan="1" colspan="1">28.1 (5.5)</td><td valign="top" align="center" rowspan="1" colspan="1">28.2 (5.7)</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">30.1 (5.6)</td><td valign="top" align="center" rowspan="1" colspan="1">32.0 (6.8)</td><td valign="top" align="center" rowspan="1" colspan="1">27.7 (6.5)</td><td valign="top" align="center" rowspan="1" colspan="1">27.8 (5.1)</td><td valign="top" align="center" rowspan="1" colspan="1">27.0 (4.7)</td><td valign="top" align="center" rowspan="1" colspan="1">27.1 (4.6)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Hypertension, <italic>n</italic> (%)</td><td valign="top" align="center" rowspan="1" colspan="1">7 (6.3)</td><td valign="top" align="center" rowspan="1" colspan="1">7 (5.9)</td><td valign="top" align="center" rowspan="1" colspan="1">720 (87.2)</td><td valign="top" align="center" rowspan="1" colspan="1">697 (85.2)</td><td valign="top" align="center" rowspan="1" colspan="1">31 (80)</td><td valign="top" align="center" rowspan="1" colspan="1">35 (88)</td><td valign="top" align="center" rowspan="1" colspan="1">86 (77.5)</td><td valign="top" align="center" rowspan="1" colspan="1">87 (79.8)</td><td valign="top" align="center" rowspan="1" colspan="1">39 (78.0)</td><td valign="top" align="center" rowspan="1" colspan="1">36 (81.8)</td><td valign="top" align="center" rowspan="1" colspan="1">98 (85.2)</td><td valign="top" align="center" rowspan="1" colspan="1">95 (81.9)</td><td valign="top" align="center" rowspan="1" colspan="1">243 (73.4)</td><td valign="top" align="center" rowspan="1" colspan="1">255 (76.3)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Diabetes, <italic>n</italic> (%)</td><td valign="top" align="center" rowspan="1" colspan="1">81 (73.0)</td><td valign="top" align="center" rowspan="1" colspan="1">84 (71.2)</td><td valign="top" align="center" rowspan="1" colspan="1">236 (28.6)</td><td valign="top" align="center" rowspan="1" colspan="1">235 (28.7)</td><td valign="top" align="center" rowspan="1" colspan="1">8 (21)</td><td valign="top" align="center" rowspan="1" colspan="1">13 (33)</td><td valign="top" align="center" rowspan="1" colspan="1">41 (36.9)</td><td valign="top" align="center" rowspan="1" colspan="1">36 (32.7)</td><td valign="top" align="center" rowspan="1" colspan="1">15 (30.0)</td><td valign="top" align="center" rowspan="1" colspan="1">15 (30.0)</td><td valign="top" align="center" rowspan="1" colspan="1">21 (18.3)</td><td valign="top" align="center" rowspan="1" colspan="1">27 (23.3)</td><td valign="top" align="center" rowspan="1" colspan="1">78 (23.6)</td><td valign="top" align="center" rowspan="1" colspan="1">85 (25.4)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Congestive heart failure, <italic>n</italic> (%)</td><td valign="top" align="center" rowspan="1" colspan="1">35 (31.5)</td><td valign="top" align="center" rowspan="1" colspan="1">36 (30.5)</td><td valign="top" align="center" rowspan="1" colspan="1">394 (47.7)</td><td valign="top" align="center" rowspan="1" colspan="1">380 (46.5)</td><td valign="top" align="center" rowspan="1" colspan="1">14 (36)</td><td valign="top" align="center" rowspan="1" colspan="1">18 (45)</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">52 (45.2)</td><td valign="top" align="center" rowspan="1" colspan="1">52 (44.8)</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Ejection fraction (mean)</td><td valign="top" align="center" rowspan="1" colspan="1">17 (15.3)</td><td valign="top" align="center" rowspan="1" colspan="1">12 (10.2)</td><td valign="top" align="center" rowspan="1" colspan="1">57.4 (10.9)</td><td valign="top" align="center" rowspan="1" colspan="1">58.2 (11.2)</td><td valign="top" align="center" rowspan="1" colspan="1">54 (8)</td><td valign="top" align="center" rowspan="1" colspan="1">51 (12)</td><td valign="top" align="center" rowspan="1" colspan="1">55 (12)</td><td valign="top" align="center" rowspan="1" colspan="1">54 (13)</td><td valign="top" align="center" rowspan="1" colspan="1">64.2 (8.9)</td><td valign="top" align="center" rowspan="1" colspan="1">67.1 (3.1)</td><td valign="top" align="center" rowspan="1" colspan="1">55 (11)</td><td valign="top" align="center" rowspan="1" colspan="1">56 (10)</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">NYHA III/IV, <italic>n</italic> (%)</td><td valign="top" align="center" rowspan="1" colspan="1">64.4 (10.0)</td><td valign="top" align="center" rowspan="1" colspan="1">64.2 (9.5)</td><td valign="top" align="center" rowspan="1" colspan="1">250 (30.3)</td><td valign="top" align="center" rowspan="1" colspan="1">222 (27.1)</td><td valign="top" align="center" rowspan="1" colspan="1">23 (59.0)</td><td valign="top" align="center" rowspan="1" colspan="1">26 (65.0)</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">12 (24.0)</td><td valign="top" align="center" rowspan="1" colspan="1">8 (18.2)</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">212 (64.0)</td><td valign="top" align="center" rowspan="1" colspan="1">220 (65.9)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Previous stroke, <italic>n</italic> (%)</td><td valign="top" align="center" rowspan="1" colspan="1">30 (27.0)</td><td valign="top" align="center" rowspan="1" colspan="1">31 (26.3)</td><td valign="top" align="center" rowspan="1" colspan="1">51 (6.2)</td><td valign="top" align="center" rowspan="1" colspan="1">35 (4.3)</td><td valign="top" align="center" rowspan="1" colspan="1">4 (10.0)</td><td valign="top" align="center" rowspan="1" colspan="1">2 (5.0)</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">0 (0.0)</td><td valign="top" align="center" rowspan="1" colspan="1">1 (2.3)</td><td valign="top" align="center" rowspan="1" colspan="1">11 (9.6)</td><td valign="top" align="center" rowspan="1" colspan="1">6 (5.2)</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">PVD, <italic>n</italic> (%)</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">83 (10.0)</td><td valign="top" align="center" rowspan="1" colspan="1">82 (10.0)</td><td valign="top" align="center" rowspan="1" colspan="1">4 (10.0)</td><td valign="top" align="center" rowspan="1" colspan="1">3 (8.0)</td><td valign="top" align="center" rowspan="1" colspan="1">28 (25.2)</td><td valign="top" align="center" rowspan="1" colspan="1">22 (20.0)</td><td valign="top" align="center" rowspan="1" colspan="1">1 (2.0)</td><td valign="top" align="center" rowspan="1" colspan="1">1 (2.3)</td><td valign="top" align="center" rowspan="1" colspan="1">10 (8.7)</td><td valign="top" align="center" rowspan="1" colspan="1">10 (8.6)</td><td valign="top" align="center" rowspan="1" colspan="1">47 (14.2)</td><td valign="top" align="center" rowspan="1" colspan="1">68 (20.4)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">VTE, <italic>n</italic> (%)</td><td valign="top" align="center" rowspan="1" colspan="1">7 (6.3)</td><td valign="top" align="center" rowspan="1" colspan="1">11 (9.3)</td><td valign="top" align="center" rowspan="1" colspan="1">18 (2.2)</td><td valign="top" align="center" rowspan="1" colspan="1">15 (1.8)</td><td valign="top" align="center" rowspan="1" colspan="1">7 (18)</td><td valign="top" align="center" rowspan="1" colspan="1">10 (25.0)</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">1 (0.9)</td><td valign="top" align="center" rowspan="1" colspan="1">1 (0.9)</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">COPD, <italic>n</italic> (%)</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">110 (13.3)</td><td valign="top" align="center" rowspan="1" colspan="1">88 (10.8)</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">33 (30.0)</td><td valign="top" align="center" rowspan="1" colspan="1">28 (25.2)</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">19 (16.5)</td><td valign="top" align="center" rowspan="1" colspan="1">16 (13.8)</td><td valign="top" align="center" rowspan="1" colspan="1">52 (15.7)</td><td valign="top" align="center" rowspan="1" colspan="1">74 (22.2)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Mean GFR (ml/min/1.73&#x02005;m<sup>2</sup>)</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">73.4 (23.8)</td><td valign="top" align="center" rowspan="1" colspan="1">73.2 (23.2)</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">73.6 (19.2)</td><td valign="top" align="center" rowspan="1" colspan="1">76,6 (19.4)</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">CKD, <italic>n</italic> (%)</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">5 (13.0)</td><td valign="top" align="center" rowspan="1" colspan="1">6 (15.0)</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">1 (2.0)</td><td valign="top" align="center" rowspan="1" colspan="1">1 (2.3)</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">STS core</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">4.0 (3.2)</td><td valign="top" align="center" rowspan="1" colspan="1">4.3 (3.5)</td><td valign="top" align="center" rowspan="1" colspan="1">8 (5.0)</td><td valign="top" align="center" rowspan="1" colspan="1">7 (3.0)</td><td valign="top" align="center" rowspan="1" colspan="1">6.2 (4.4)</td><td valign="top" align="center" rowspan="1" colspan="1">6.4 (4.6)</td><td valign="top" align="center" rowspan="1" colspan="1">1.5 (0.5)</td><td valign="top" align="center" rowspan="1" colspan="1">1.4 (0.5)</td><td valign="top" align="center" rowspan="1" colspan="1">2.8 (1.5)</td><td valign="top" align="center" rowspan="1" colspan="1">3.0 (2.1)</td><td valign="top" align="center" rowspan="1" colspan="1">2.6 (1.6)</td><td valign="top" align="center" rowspan="1" colspan="1">2.4 (1.7)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">PCI, <italic>n</italic> (%)</td><td valign="top" align="center" rowspan="1" colspan="1">3.1 (2.1)</td><td valign="top" align="center" rowspan="1" colspan="1">3.5 (2.7)</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">9 (23.0)</td><td valign="top" align="center" rowspan="1" colspan="1">12 (30.0)</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">6 (12.0)</td><td valign="top" align="center" rowspan="1" colspan="1">4 (9.1)</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Previous pacemaker, <italic>n</italic> (%)</td><td valign="top" align="center" rowspan="1" colspan="1">18 (16.2)</td><td valign="top" align="center" rowspan="1" colspan="1">14 (11.9)</td><td valign="top" align="center" rowspan="1" colspan="1">80 (9.7)</td><td valign="top" align="center" rowspan="1" colspan="1">80 (9.8)</td><td valign="top" align="center" rowspan="1" colspan="1">1 (3.0)</td><td valign="top" align="center" rowspan="1" colspan="1">4 (10.0)</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">1 (2.0)</td><td valign="top" align="center" rowspan="1" colspan="1">0 (0.0)</td><td valign="top" align="center" rowspan="1" colspan="1">14 (12.2)</td><td valign="top" align="center" rowspan="1" colspan="1">14 (12.1)</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Euro SCORE</td><td valign="top" align="center" rowspan="1" colspan="1">13 (11.7)</td><td valign="top" align="center" rowspan="1" colspan="1">13 (11.0)</td><td valign="top" align="center" rowspan="1" colspan="1">4.1 (3.9)</td><td valign="top" align="center" rowspan="1" colspan="1">4.1 (3.7)</td><td valign="top" align="center" rowspan="1" colspan="1">21 (16)</td><td valign="top" align="center" rowspan="1" colspan="1">23 (15)</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Aortic valve area, (cm<sup>2</sup>)</td><td valign="top" align="center" rowspan="1" colspan="1">2.3 (3.5)</td><td valign="top" align="center" rowspan="1" colspan="1">2.4 (2.1)</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">0.85 (0.2)</td><td valign="top" align="center" rowspan="1" colspan="1">0.82 (0.2)</td><td valign="top" align="center" rowspan="1" colspan="1">1.8 (0.5)</td><td valign="top" align="center" rowspan="1" colspan="1">1.8 (0.5)</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Mean gradient post procedure(mm Hg)</td><td valign="top" align="center" rowspan="1" colspan="1">1.7 (0.4)</td><td valign="top" align="center" rowspan="1" colspan="1">1.6 (0.4)</td><td valign="top" align="center" rowspan="1" colspan="1">10.1 (4.7)</td><td valign="top" align="center" rowspan="1" colspan="1">10.1 (4.6)</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">10.8 (5.3)</td><td valign="top" align="center" rowspan="1" colspan="1">10.3 (5.7)</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Paravalvular regurgitation post, <italic>n</italic> (%)Mild</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">157 (19.0)</td><td valign="top" align="center" rowspan="1" colspan="1">168 (20.5)</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">28 (29.2)</td><td valign="top" align="center" rowspan="1" colspan="1">24 (25.0)</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">19 (16.5)</td><td valign="top" align="center" rowspan="1" colspan="1">19 (16.4)</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Moderate or severe</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">10 (1.2)</td><td valign="top" align="center" rowspan="1" colspan="1">10 (1.2)</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">9 (9.4)</td><td valign="top" align="center" rowspan="1" colspan="1">6 (6.3)</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">2 (1.7)</td><td valign="top" align="center" rowspan="1" colspan="1">1 (0.9)</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Previous CABG, <italic>n</italic> (%)</td><td valign="top" align="center" rowspan="1" colspan="1">3 (2.8)</td><td valign="top" align="center" rowspan="1" colspan="1">3 (2.7)</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">4 (10)</td><td valign="top" align="center" rowspan="1" colspan="1">2 (5)</td><td valign="top" align="center" rowspan="1" colspan="1">39 (35.1)</td><td valign="top" align="center" rowspan="1" colspan="1">42 (38.5)</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">61 (18.4)</td><td valign="top" align="center" rowspan="1" colspan="1">65 (19.5)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Previous myocardial infarction, <italic>n</italic> (%)</td><td valign="top" align="center" rowspan="1" colspan="1">2 (1.8)</td><td valign="top" align="center" rowspan="1" colspan="1">3 (2.5)</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">4 (10)</td><td valign="top" align="center" rowspan="1" colspan="1">7 (18)</td><td valign="top" align="center" rowspan="1" colspan="1">26 (23.4)</td><td valign="top" align="center" rowspan="1" colspan="1">20 (18.4)</td><td valign="top" align="center" rowspan="1" colspan="1">2 (4.0)</td><td valign="top" align="center" rowspan="1" colspan="1">0 (0.0)</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">28 (8.5)</td><td valign="top" align="center" rowspan="1" colspan="1">31 (9.3)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Previous TIA, <italic>n</italic> (%)</td><td valign="top" align="center" rowspan="1" colspan="1">1 (0.9)</td><td valign="top" align="center" rowspan="1" colspan="1">2 (1.7)</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">2 (5)</td><td valign="top" align="center" rowspan="1" colspan="1">2 (5)</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Previous history of heart surgery, <italic>n</italic> (%)</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">1 (3)</td><td valign="top" align="center" rowspan="1" colspan="1">2 (5)</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn id="table-fn2"><p>BMI, body mass index; PVD, peripheral vascular disease; VTE, venous thromboembolism; COPD, chronic obstructive pulmonary disease; GFR, <sans-serif>g</sans-serif>lomerular filtration rate; CKD, chronic kidney disease; STS, society of thoracic surgeon; PCI, percutaneous coronary intervention; CABG, coronary artery bypass grafting; TIA, transient ischemic attack.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s3c"><title>Bias risk assessment</title><p>Because all of them are open labels, the overall implementation bias risk is high, and there are other bias risks in Dangas 2019, Josep 2017, and Rogers 2021. See <xref rid="F2" ref-type="fig">Figure 2</xref> for details.</p></sec><sec id="s3d"><title>Safety endpoints</title><p>This study included all-cause mortality events in seven studies, cardiovascular death in four studies, major bleeding and life-threatening bleeding in seven studies, and minor bleeding in three studies. Compared with DOAC, there were no significant differences in all-cause mortality, cardiovascular mortality, and minor bleeding safety events. The rates of major bleeding and life-threatening bleeding in the SAPT group were lower than those in the DOAC group (OR: 0.68; 95% CI: 0.47&#x02013;0.99). A detailed summary is provided in <xref rid="F3" ref-type="fig">Figure&#x000a0;3</xref>.</p><fig position="float" id="F3"><label>Figure 3</label><caption><p>Safety endpoints: <bold>(A)</bold> all-cause mortality; <bold>(B)</bold> cardiovascular mortality; <bold>(C)</bold> major bleeding and life-threatening bleeding; <bold>(D)</bold> minor bleeding.</p></caption><graphic xlink:href="fcvm-12-1496334-g003" position="float"/></fig></sec><sec id="s3e"><title>Efficacy endpoints</title><p>Among the efficacy endpoints, ischemic stroke/TIA was reported in seven studies, systemic embolism in two studies, HALT in three studies, and RELM in three studies. Compared to DOAC, no significant differences were observed in any of these endpoints (all <italic>p</italic>&#x02009;&#x0003e;&#x02009;0.05). Comprehensive comparisons are detailed in <xref rid="F4" ref-type="fig">Figure&#x000a0;4</xref>.</p><fig position="float" id="F4"><label>Figure 4</label><caption><p>Efficacy endpoints: <bold>(A)</bold> ischemic stroke/TIA; <bold>(B)</bold> systemic embolism; <bold>(C)</bold> HALT; <bold>(D)</bold> RELM.</p></caption><graphic xlink:href="fcvm-12-1496334-g004" position="float"/></fig></sec></sec><sec sec-type="discussion" id="s4"><title>Discussion</title><p>This network meta-analysis evaluated the safety and efficacy of various antithrombotic regimens for patients without an indication for OAC after TAVR. Seven randomized controlled trials were included in this analysis. The results indicated that patients receiving SAPT demonstrated lower incidence of major and life-threatening bleeding 3&#x02013;24 months post-TAVR compared to those treated with DOAC therapy.</p><p>Currently, large-scale RCTs establish TAVR as the leading transcatheter approach for aortic valve replacement in symptomatic patients (<xref rid="B18" ref-type="bibr">18</xref>, <xref rid="B19" ref-type="bibr">19</xref>). Despite its success in treating aortic stenosis, the optimal antithrombotic strategy to balance thrombosis and bleeding risks post-procedure remains uncertain (<xref rid="B20" ref-type="bibr">20</xref>, <xref rid="B21" ref-type="bibr">21</xref>).</p><p>The basic principle of antithrombotic therapy after TAVR is to balance the prevention of leaflet thrombosis (driven by the thrombogenicity of bioprosthetic valve materials and altered hemodynamics) with the risk of bleeding (<xref rid="B22" ref-type="bibr">22</xref>). Currently, the ESC/EACTS 2021 and American College of Cardiology/American Heart Association (ACC/AHA) guidelines recommend SAPT for patients not on anticoagulation after TAVR (<xref rid="B5" ref-type="bibr">5</xref>). While previous studies suggest that DOACs may reduce bleeding events compared to VKAs (<xref rid="B23" ref-type="bibr">23</xref>), our analysis demonstrates that SAPT achieves an optimal balance between preventing thrombotic events and minimizing bleeding risks compared to DOACs, aligning with the primary goal of post-TAVR antithrombotic management. This finding is consistent with Rodes-Cabau et al.'s study (<xref rid="B14" ref-type="bibr">14</xref>), which compared SAPT with DAPT, further supporting guideline recommendations to prioritize SAPT in patients without OAC indications. Patient-specific factors, including advanced age and comorbidities (e.g., atrial fibrillation requiring OAC), as well as the use of non-DOAC anticoagulants (e.g., VKAs), are independently associated with elevated post-TAVR bleeding risk (<xref rid="B24" ref-type="bibr">24</xref>). Given that most TAVR recipients are elderly with multiple complications, tailoring treatment to individual anticoagulation needs is crucial to mitigate both bleeding and thromboembolic risks (<xref rid="B6" ref-type="bibr">6</xref>).</p><p>Subclinical leaflet thrombosis after TAVR is frequently observed (<xref rid="B25" ref-type="bibr">25</xref>). This condition causes HALT, visible via 4D computed tomography (CT) imaging, with or without RELM (<xref rid="B26" ref-type="bibr">26</xref>, <xref rid="B27" ref-type="bibr">27</xref>). Observational studies report a correlation between stroke or TIA after TAVR and valvular thrombosis, with stroke or TIA increasing the incidence of valvular thrombosis (<xref rid="B27" ref-type="bibr">27</xref>). Our network meta-analysis found no significant difference in ischemic stroke or TIA events, systemic embolism, HALT, and RELM between DOAC and other treatment strategies. DOACs were not associated with a reduction in the incidence of RELM and HALT compared to other treatment strategies, which differs from the findings of Mohamed Abuelazm's meta-analysis (<xref rid="B7" ref-type="bibr">7</xref>). The research compared DOACs with standard care, including vitamin K antagonists, DAPT, or SAPT, but did not specifically compare SAPT, DAPT, and VKA groups. Our comparison of standard care details among groups may explain the different results. The impact of Subclinical leaflet thrombosis on clinical outcomes after TAVR remains unclear, with some reports suggesting it is not a decisive factor in evaluating different antithrombotic methods (<xref rid="B26" ref-type="bibr">26</xref>). In the future, subclinical leaflet thrombosis may be a valuable antithrombotic indication for post-TAVR patients. However, randomized controlled studies are needed to clarify the relationship between stroke or TIA and valvular thrombosis.</p><p>In summary, our network meta-analysis indicates that DOACs are less effective than SAPT regarding safety and efficacy in patients without anticoagulation indications after TAVR. The impact of subclinical leaflet thrombosis on clinical outcomes after TAVR remains unclear and requires further investigation.</p></sec><sec id="s5"><title>Limitations</title><p>Our research has several limitations. Firstly, as a network meta-analysis, we have limited ability to explain the heterogeneity among studies. There were some anticoagulated patients in Popular TAVI (subgroup A), which may increase the heterogeneity of our study. Secondly, we included seven randomized controlled trials but excluded retrospective studies. Additionally, the sample size was insufficient, limiting the generalizability of our results. Finally, the study varied in terms of timing, usage and dosage, valve type, and patient risk levels related to antithrombotic strategies. Future research is needed to further verify these results.</p></sec><sec sec-type="conclusions" id="s6"><title>Conclusion</title><p>The results of the network meta-analysis indicate that DOAC is less effective than SAPT for safety and efficacy in patients without anticoagulation indications following TAVR. Thus, SAPT remains the optimal choice for postoperative care.</p></sec></body><back><sec sec-type="data-availability" id="s7"><title>Data availability statement</title><p>The original contributions presented in the study are included in the article/<xref rid="s11" ref-type="sec">Supplementary Material</xref>, further inquiries can be directed to the corresponding author.</p></sec><sec sec-type="author-contributions" id="s8"><title>Author contributions</title><p>MS: Conceptualization, Data curation, Investigation, Software, Writing &#x02013; original draft, Writing &#x02013; review &#x00026; editing. YW: Funding acquisition, Methodology, Project administration, Resources, Supervision, Writing &#x02013; review &#x00026; editing. ZQ: Funding acquisition, Methodology, Resources, Supervision, Writing &#x02013; original draft.</p></sec><sec sec-type="COI-statement" id="s10"><title>Conflict of interest</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec><sec sec-type="disclaimer" id="s12"><title>Publisher's note</title><p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p></sec><sec sec-type="supplementary-material" id="s11"><title>Supplementary material</title><p>The Supplementary Material for this article can be found online at: <ext-link xlink:href="https://www.frontiersin.org/articles/10.3389/fcvm.2025.1496334/full#supplementary-material" ext-link-type="uri">https://www.frontiersin.org/articles/10.3389/fcvm.2025.1496334/full#supplementary-material</ext-link></p><supplementary-material id="SD1" position="float" content-type="local-data"><media xlink:href="Table1.docx" id="d100e1443" position="anchor"/></supplementary-material></sec><ref-list><title>References</title><ref id="B1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reardon</surname><given-names>MJ</given-names></name><name><surname>Van Mieghem</surname><given-names>NM</given-names></name><name><surname>Popma</surname><given-names>JJ</given-names></name><name><surname>Kleiman</surname><given-names>NS</given-names></name><name><surname>Sondergaard</surname><given-names>L</given-names></name><name><surname>Mumtaz</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>Surgical or transcatheter aortic-valve replacement in intermediate-risk patients</article-title>. <source>N Engl J Med</source>. (<year>2017</year>) <volume>376</volume>(<issue>14</issue>):<fpage>1321</fpage>&#x02013;<lpage>31</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa1700456</pub-id><pub-id pub-id-type="pmid">28304219</pub-id>
</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Greco</surname><given-names>A</given-names></name><name><surname>Capodanno</surname><given-names>D</given-names></name></person-group>. <article-title>Anticoagulation after transcatheter aortic valve implantation: current Status</article-title>. <source>Interv Cardiol</source>. (<year>2020</year>) <volume>15</volume>:<fpage>e02</fpage>. <pub-id pub-id-type="doi">10.15420/icr.2019.24</pub-id><pub-id pub-id-type="pmid">32382318</pub-id>
</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sattar</surname><given-names>Y</given-names></name><name><surname>Rauf</surname><given-names>H</given-names></name><name><surname>Bareeqa</surname><given-names>SB</given-names></name><name><surname>Ullah</surname><given-names>W</given-names></name><name><surname>Myla</surname><given-names>M</given-names></name></person-group>. <article-title>Transcatheter aortic valve replacement versus surgical aortic valve replacement: a review of aortic stenosis management</article-title>. <source>Cureus</source>. (<year>2019</year>) <volume>11</volume>(<issue>12</issue>):<fpage>e6431</fpage>. <pub-id pub-id-type="doi">10.7759/cureus.6431</pub-id><pub-id pub-id-type="pmid">31993269</pub-id>
</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Baal</surname><given-names>J</given-names></name><name><surname>Roszek</surname><given-names>B</given-names></name><name><surname>van Elk</surname><given-names>M</given-names></name><name><surname>Geertsma</surname><given-names>RE</given-names></name></person-group>. <article-title>Transcatheter aortic valve replacement: clinical safety and performance data</article-title>. <source>Expert Rev Med Devices</source>. (<year>2019</year>) <volume>16</volume>(<issue>10</issue>):<fpage>899</fpage>&#x02013;<lpage>911</lpage>. <pub-id pub-id-type="doi">10.1080/17434440.2019.1674138</pub-id><pub-id pub-id-type="pmid">31564181</pub-id>
</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Otto</surname><given-names>CM</given-names></name><name><surname>Nishimura</surname><given-names>RA</given-names></name><name><surname>Bonow</surname><given-names>RO</given-names></name><name><surname>Carabello</surname><given-names>BA</given-names></name><name><surname>Erwin</surname><given-names>JP</given-names><suffix>3rd</suffix></name><name><surname>Gentile</surname><given-names>F</given-names></name><etal/></person-group>
<article-title>2020 ACC/AHA guideline for the management of patients with valvular heart disease: executive summary: a report of the American college of cardiology/American heart association joint committee on clinical practice guidelines</article-title>. <source>Circulation</source>. (<year>2021</year>) <volume>143</volume>(<issue>5</issue>):<fpage>e35</fpage>&#x02013;<lpage>71</lpage>. <pub-id pub-id-type="doi">10.1161/CIR.0000000000000932</pub-id><pub-id pub-id-type="pmid">33332149</pub-id>
</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dangas</surname><given-names>GD</given-names></name><name><surname>Tijssen</surname><given-names>JGP</given-names></name><name><surname>Wohrle</surname><given-names>J</given-names></name><name><surname>Sondergaard</surname><given-names>L</given-names></name><name><surname>Gilard</surname><given-names>M</given-names></name><name><surname>Mollmann</surname><given-names>H</given-names></name><etal/></person-group>
<article-title>A controlled trial of rivaroxaban after transcatheter aortic-valve replacement</article-title>. <source>N Engl J Med</source>. (<year>2020</year>) <volume>382</volume>(<issue>2</issue>):<fpage>120</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa1911425</pub-id><pub-id pub-id-type="pmid">31733180</pub-id>
</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abuelazm</surname><given-names>M</given-names></name><name><surname>Abdelazeem</surname><given-names>B</given-names></name><name><surname>Katamesh</surname><given-names>BE</given-names></name><name><surname>Gamal</surname><given-names>M</given-names></name><name><surname>Simhachalam Kutikuppala</surname><given-names>LV</given-names></name><name><surname>Kheiri</surname><given-names>B</given-names></name><etal/></person-group>
<article-title>The efficacy and safety of direct oral anticoagulants versus standard of care in patients without an indication of anti-coagulants after transcatheter aortic valve replacement: a meta-analysis of randomized controlled trials</article-title>. <source>J Clin Med</source>. (<year>2022</year>) <volume>11</volume>(<issue>22</issue>):<fpage>6781</fpage>. <pub-id pub-id-type="doi">10.3390/jcm11226781</pub-id>.<pub-id pub-id-type="pmid">36431258</pub-id>
</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Navarese</surname><given-names>EP</given-names></name><name><surname>Grisafi</surname><given-names>L</given-names></name><name><surname>Spinoni</surname><given-names>EG</given-names></name><name><surname>Mennuni</surname><given-names>MG</given-names></name><name><surname>Rognoni</surname><given-names>A</given-names></name><name><surname>Ratajczak</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>Safety and efficacy of different antithrombotic strategies after transcatheter aortic valve implantation: a network meta-analysis</article-title>. <source>Thromb Haemost</source>. (<year>2022</year>) <volume>122</volume>(<issue>2</issue>):<fpage>216</fpage>&#x02013;<lpage>25</lpage>. <pub-id pub-id-type="doi">10.1055/a-1496-8114</pub-id><pub-id pub-id-type="pmid">33930901</pub-id>
</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Montalescot</surname><given-names>G</given-names></name><name><surname>Redheuil</surname><given-names>A</given-names></name><name><surname>Vincent</surname><given-names>F</given-names></name><name><surname>Desch</surname><given-names>S</given-names></name><name><surname>De Benedictis</surname><given-names>M</given-names></name><name><surname>Eltchaninoff</surname><given-names>H</given-names></name><etal/></person-group>
<article-title>Apixaban and valve thrombosis after transcatheter aortic valve replacement: the ATLANTIS-4D-CT randomized clinical trial substudy</article-title>. <source>JACC Cardiovasc Interv</source>. (<year>2022</year>) <volume>15</volume>(<issue>18</issue>):<fpage>1794</fpage>&#x02013;<lpage>804</lpage>. <pub-id pub-id-type="doi">10.1016/j.jcin.2022.07.014</pub-id><pub-id pub-id-type="pmid">36137682</pub-id>
</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Page</surname><given-names>MJ</given-names></name><name><surname>Moher</surname><given-names>D</given-names></name><name><surname>Bossuyt</surname><given-names>PM</given-names></name><name><surname>Boutron</surname><given-names>I</given-names></name><name><surname>Hoffmann</surname><given-names>TC</given-names></name><name><surname>Mulrow</surname><given-names>CD</given-names></name><etal/></person-group>
<article-title>PRISMA 2020 Explanation and elaboration: updated guidance and exemplars for reporting systematic reviews</article-title>. <source>Br Med J</source>. (<year>2021</year>) <volume>372</volume>:<fpage>n160</fpage>. <pub-id pub-id-type="doi">10.1136/bmj.n160</pub-id><pub-id pub-id-type="pmid">33781993</pub-id>
</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Higgins</surname><given-names>JPT</given-names></name><name><surname>Thomas</surname><given-names>J</given-names></name><name><surname>Chandler</surname><given-names>J</given-names></name><name><surname>Cumpston</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>T</given-names></name><name><surname>Page</surname><given-names>MJ</given-names></name><etal/></person-group>
<source>Cochrane Handbook for Systematic Reviews of Interventions&#x02014;2019</source>. <publisher-loc>London, UK</publisher-loc>: <publisher-name>The Cochrane Collaboration</publisher-name> (<year>2019</year>). p. <fpage>1</fpage>&#x02013;<lpage>694</lpage>. <pub-id pub-id-type="doi">10.1002/9781119536604</pub-id></mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>DW</given-names></name><name><surname>Ahn</surname><given-names>JM</given-names></name><name><surname>Kang</surname><given-names>DY</given-names></name><name><surname>Kim</surname><given-names>KW</given-names></name><name><surname>Koo</surname><given-names>HJ</given-names></name><name><surname>Yang</surname><given-names>DH</given-names></name><etal/></person-group>
<article-title>Edoxaban versus dual antiplatelet therapy for leaflet thrombosis and cerebral thromboembolism after TAVR: the ADAPT-TAVR randomized clinical trial</article-title>. <source>Circulation</source>. (<year>2022</year>) <volume>146</volume>(<issue>6</issue>):<fpage>466</fpage>&#x02013;<lpage>79</lpage>. <pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.122.059512</pub-id><pub-id pub-id-type="pmid">35373583</pub-id>
</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ussia</surname><given-names>GP</given-names></name><name><surname>Scarabelli</surname><given-names>M</given-names></name><name><surname>Mule</surname><given-names>M</given-names></name><name><surname>Barbanti</surname><given-names>M</given-names></name><name><surname>Sarkar</surname><given-names>K</given-names></name><name><surname>Cammalleri</surname><given-names>V</given-names></name><etal/></person-group>
<article-title>Dual antiplatelet therapy versus aspirin alone in patients undergoing transcatheter aortic valve implantation</article-title>. <source>Am J Cardiol</source>. (<year>2011</year>) <volume>108</volume>(<issue>12</issue>):<fpage>1772</fpage>&#x02013;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1016/j.amjcard.2011.07.049</pub-id><pub-id pub-id-type="pmid">21907949</pub-id>
</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rodes-Cabau</surname><given-names>J</given-names></name><name><surname>Masson</surname><given-names>JB</given-names></name><name><surname>Welsh</surname><given-names>RC</given-names></name><name><surname>Garcia Del Blanco</surname><given-names>B</given-names></name><name><surname>Pelletier</surname><given-names>M</given-names></name><name><surname>Webb</surname><given-names>JG</given-names></name><etal/></person-group>
<article-title>Aspirin versus aspirin plus clopidogrel as antithrombotic treatment following transcatheter aortic valve replacement with a balloon-expandable valve: the ARTE (aspirin versus aspirin&#x02009;+&#x02009;clopidogrel following transcatheter aortic valve implantation) randomized clinical trial</article-title>. <source>JACC Cardiovasc Interv</source>. (<year>2017</year>) <volume>10</volume>(<issue>13</issue>):<fpage>1357</fpage>&#x02013;<lpage>65</lpage>. <pub-id pub-id-type="doi">10.1016/j.jcin.2017.04.014</pub-id><pub-id pub-id-type="pmid">28527771</pub-id>
</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rogers</surname><given-names>T</given-names></name><name><surname>Shults</surname><given-names>C</given-names></name><name><surname>Torguson</surname><given-names>R</given-names></name><name><surname>Shea</surname><given-names>C</given-names></name><name><surname>Parikh</surname><given-names>P</given-names></name><name><surname>Bilfinger</surname><given-names>T</given-names></name><etal/></person-group>
<article-title>Randomized trial of aspirin versus warfarin after transcatheter aortic valve replacement in low-risk patients</article-title>. <source>Circ Cardiovasc Interv</source>. (<year>2021</year>) <volume>14</volume>(<issue>1</issue>):<fpage>e009983</fpage>. <pub-id pub-id-type="doi">10.1161/CIRCINTERVENTIONS.120.009983</pub-id><pub-id pub-id-type="pmid">33423540</pub-id>
</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Backer</surname><given-names>O</given-names></name><name><surname>Dangas</surname><given-names>GD</given-names></name><name><surname>Jilaihawi</surname><given-names>H</given-names></name><name><surname>Leipsic</surname><given-names>JA</given-names></name><name><surname>Terkelsen</surname><given-names>CJ</given-names></name><name><surname>Makkar</surname><given-names>R</given-names></name><etal/></person-group>
<article-title>Reduced leaflet motion after transcatheter aortic-valve replacement</article-title>. <source>N Engl J Med</source>. (<year>2020</year>) <volume>382</volume>(<issue>2</issue>):<fpage>130</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa1911426</pub-id><pub-id pub-id-type="pmid">31733182</pub-id>
</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brouwer</surname><given-names>J</given-names></name><name><surname>Nijenhuis</surname><given-names>VJ</given-names></name><name><surname>Delewi</surname><given-names>R</given-names></name><name><surname>Hermanides</surname><given-names>RS</given-names></name><name><surname>Holvoet</surname><given-names>W</given-names></name><name><surname>Dubois</surname><given-names>CLF</given-names></name><etal/></person-group>
<article-title>Aspirin with or without clopidogrel after transcatheter aortic-valve implantation</article-title>. <source>N Engl J Med</source>. (<year>2020</year>) <volume>383</volume>(<issue>15</issue>):<fpage>1447</fpage>&#x02013;<lpage>57</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa2017815</pub-id><pub-id pub-id-type="pmid">32865376</pub-id>
</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huynh</surname><given-names>K</given-names></name></person-group>. <article-title>TAVR Versus surgery in low-risk patients</article-title>. <source>Nat Rev Cardiol</source>. (<year>2019</year>) <volume>16</volume>(<issue>6</issue>):<fpage>319</fpage>. <pub-id pub-id-type="doi">10.1038/s41569-019-0197-y</pub-id><pub-id pub-id-type="pmid">30944409</pub-id>
</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Popma</surname><given-names>JJ</given-names></name><name><surname>Deeb</surname><given-names>GM</given-names></name><name><surname>Yakubov</surname><given-names>SJ</given-names></name><name><surname>Mumtaz</surname><given-names>M</given-names></name><name><surname>Gada</surname><given-names>H</given-names></name><name><surname>O'Hair</surname><given-names>D</given-names></name><etal/></person-group>
<article-title>Transcatheter aortic-valve replacement with a self-expanding valve in low-risk patients</article-title>. <source>N Engl J Med</source>. (<year>2019</year>) <volume>380</volume>(<issue>18</issue>):<fpage>1706</fpage>&#x02013;<lpage>15</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa1816885</pub-id><pub-id pub-id-type="pmid">30883053</pub-id>
</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Capodanno</surname><given-names>D</given-names></name><name><surname>Angiolillo</surname><given-names>DJ</given-names></name></person-group>. <article-title>Tailoring antiplatelet therapy in patients undergoing transcatheter aortic valve replacement: navigating the unknown</article-title>. <source>JACC Cardiovasc Interv</source>. (<year>2019</year>) <volume>12</volume>(<issue>1</issue>):<fpage>33</fpage>&#x02013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1016/j.jcin.2018.10.047</pub-id><pub-id pub-id-type="pmid">30621975</pub-id>
</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Han</surname><given-names>Y</given-names></name></person-group>. <article-title>Antithrombotic therapy in patients undergoing transcatheter aortic valve replacement</article-title>. <source>Eur Heart J</source>. (<year>2022</year>) <volume>43</volume>(<issue>43</issue>):<fpage>4532</fpage>&#x02013;<lpage>3</lpage>. <pub-id pub-id-type="doi">10.1093/eurheartj/ehac290</pub-id><pub-id pub-id-type="pmid">36100978</pub-id>
</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maznyczka</surname><given-names>A</given-names></name><name><surname>Pilgrim</surname><given-names>T</given-names></name></person-group>. <article-title>Antithrombotic treatment after transcatheter valve interventions: current Status and future directions</article-title>. <source>Clin Ther</source>. (<year>2024</year>) <volume>46</volume>(<issue>2</issue>):<fpage>122</fpage>&#x02013;<lpage>33</lpage>. <pub-id pub-id-type="doi">10.1016/j.clinthera.2023.09.028</pub-id><pub-id pub-id-type="pmid">37926630</pub-id>
</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mousa</surname><given-names>TAM</given-names></name><name><surname>Mahfouz</surname><given-names>A</given-names></name><name><surname>Mohammed</surname><given-names>N</given-names></name></person-group>. <article-title>Antithrombotic therapy after transcatheter aortic valve replacement</article-title>. <source>Heart Views</source>. (<year>2022</year>) <volume>23</volume>(<issue>1</issue>):<fpage>10</fpage>&#x02013;<lpage>5</lpage>. <pub-id pub-id-type="doi">10.4103/heartviews.heartviews_36_22</pub-id><pub-id pub-id-type="pmid">35757447</pub-id>
</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Capodanno</surname><given-names>D</given-names></name><name><surname>Collet</surname><given-names>JP</given-names></name><name><surname>Dangas</surname><given-names>G</given-names></name><name><surname>Montalescot</surname><given-names>G</given-names></name><name><surname>Ten Berg</surname><given-names>JM</given-names></name><name><surname>Windecker</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>Antithrombotic therapy after transcatheter aortic valve replacement</article-title>. <source>JACC Cardiovasc Interv</source>. (<year>2021</year>) <volume>14</volume>(<issue>15</issue>):<fpage>1688</fpage>&#x02013;<lpage>703</lpage>. <pub-id pub-id-type="doi">10.1016/j.jcin.2021.06.020</pub-id><pub-id pub-id-type="pmid">34353601</pub-id>
</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yanagisawa</surname><given-names>R</given-names></name><name><surname>Hayashida</surname><given-names>K</given-names></name><name><surname>Yamada</surname><given-names>Y</given-names></name><name><surname>Tanaka</surname><given-names>M</given-names></name><name><surname>Yashima</surname><given-names>F</given-names></name><name><surname>Inohara</surname><given-names>T</given-names></name><etal/></person-group>
<article-title>Incidence, predictors, and mid-term outcomes of possible leaflet thrombosis after TAVR</article-title>. <source>JACC Cardiovasc Imaging</source>. (<year>2016</year>). <pub-id pub-id-type="doi">10.1016/j.jcmg.2016.11.005</pub-id></mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dangas</surname><given-names>G</given-names></name><name><surname>Nicolas</surname><given-names>J</given-names></name></person-group>. <article-title>Anticoagulation and subclinical valve thrombosis after TAVR</article-title>. <source>JACC Cardiovasc Interv</source>. (<year>2022</year>) <volume>15</volume>(<issue>18</issue>):<fpage>1805</fpage>&#x02013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1016/j.jcin.2022.08.003</pub-id><pub-id pub-id-type="pmid">36057537</pub-id>
</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chakravarty</surname><given-names>T</given-names></name><name><surname>Sondergaard</surname><given-names>L</given-names></name><name><surname>Friedman</surname><given-names>J</given-names></name><name><surname>De Backer</surname><given-names>O</given-names></name><name><surname>Berman</surname><given-names>D</given-names></name><name><surname>Kofoed</surname><given-names>KF</given-names></name><etal/></person-group>
<article-title>Subclinical leaflet thrombosis in surgical and transcatheter bioprosthetic aortic valves: an observational study</article-title>. <source>Lancet</source>. (<year>2017</year>) <volume>389</volume>(<issue>10087</issue>):<fpage>2383</fpage>&#x02013;<lpage>92</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(17)30757-2</pub-id><pub-id pub-id-type="pmid">28330690</pub-id>
</mixed-citation></ref></ref-list></back></article>